Acute coronary syndromes
KEYWORDS: people, coronary, acute, pci, risk, acute coronary, therapy, recommendations, committee, evidence, angina, unstable, nstemi, unstable angina, offer

(NG185) licensed for early post-MI treatment. [2007] 1.4.40 For people who have had a proven MI in the past and heart failure due to reduced left ventricular ejection fraction, treatment with an aldosterone antagonist should be in line with the NICE guideline on chronic heart failure in adults. [2007] 1.4.41 Monitor renal function and serum potassium before and during treatment with an aldosterone antagonist. If hyperkalaemia is a problem, halve the dose of the aldosterone antagonist or stop the drug. [2007] Statins and other lipid-lowering agents 1.4.42 Statin therapy is recommended for adults with clinical evidence of cardiovascular disease in line with recommendations on lipid-lowering treatment for secondary prevention in the NICE guideline on cardiovascular disease: risk assessment and reduction. [2007] 1.5 Coronary revascularisation after an MI 1.5.1 Offer a cardiological assessment to everyone who has had a previous MI, but not had coronary revascularisation to consider whether coronary revascularisation is appropriate. This should take into account comorbidity. [2007, amended 2020] 1.6 Selected patient subgroups People with reduced left ventricular ejection fraction 1.6.1 Implantable cardioverter defibrillators, cardiac resynchronisation therapy (CRT) with defibrillator or CRT with pacing are recommended as options in NICE technology appraisal guidance for treating people with heart
